| Literature DB >> 26575977 |
Teresa Bellissimo1, Emanuele Russo2, Federica Ganci3, Carmen Vico1, Andrea Sacconi3, Flavia Longo4, Domenico Vitolo5, Marco Anile2, Daniele Disio2, Mirella Marino6, Giovanni Blandino3, Federico Venuta2, Francesco Fazi1.
Abstract
Thymic epithelial cells give rise to both thymoma and thymic carcinoma. A crucial advance in thymic epithelial tumors (TET) management may derive from the identification of novel molecular biomarkers able to improve diagnosis, prognosis and treatment planning.In a previous study, we identified microRNAs that were differentially expressed in tumor vs normal thymic tissues. Among the microRNAs resulted up-regulated in TET tissues, we evaluated miR-21-5p, miR-148a-3p, miR-141-3p, miR-34b-5p, miR-34c-5p, miR-455-5p as blood plasma circulating non-invasive biomarkers for TET management.We firstly report that the expression levels of specific onco-miRNAs, that we found upregulated in the blood plasma collected from TET patients at surgery, resulted significantly reduced in follow-up samples.This pilot study suggests that circulating miR-21-5p and miR-148a-3p could represent novel non-invasive biomarkers to evaluate the efficacy of therapy and the prognosis of TET.Entities:
Keywords: Biomarkers; circulating microRNAs; miR-148a-3p; miR-21-5p; microRNAs; thymic epithelial tumors; thymoma
Mesh:
Substances:
Year: 2016 PMID: 26575977 PMCID: PMC4847810 DOI: 10.1080/15384047.2015.1108493
Source DB: PubMed Journal: Cancer Biol Ther ISSN: 1538-4047 Impact factor: 4.742